Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group

• Authors: Uma Athale, Hamilton Health Sciences; Nobuko Hijiya, Northwestern University; Briana Patterson, Emory University; Daniel Bergsagel, Emory University; Jeffrey R. Andolina, University of Rochester; Henrique Bittencourt, Ste Justine University Hospital Center; Kirk R. Schultz, British Columbia Childrens Hospital; Michael J. Burke, Childrens Hospital of Wisconsin; Michele S. Redell, Baylor College of Medicine; E. Anders Kolb, Nemours/Alfred I DuPont Hospital for Children; Donna L. Johnston, Childrens Hospital of Eastern Ontario
• Journal Title: Pediatric Blood & Cancer
• Volume: Volume 66, Number 9
• Publisher: Wiley | 2019-09-01, Pages e27827-e27827
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1002/pbc.27827
• Subjects: Health Sciences, Oncology; Health Sciences, Health Care Management; Health Sciences, Human Development
• Keywords: Science & Technology; Life Sciences & Biomedicine; Oncology; Hematology; Pediatrics; CML; pediatric; recommendations; Chronic myelogenous leukemia; Imantinib cessation; Kinase inhibitors; Young adults; Safety; Phase; Disease; Cancer

Abstract

Chronic myeloid leukemia (CML) accounts for 2-3% of leukemias in children under 15 and 9% in adolescents aged 15-19. The diagnosis and management of CML in children, adolescents, and young adults have several differences compared to that in adults. This review outlines the diagnosis and management of the underlying disease as well as challenges that can occur when dealing with CML in this patient population.